Causes of Health Disparities in African Americans With Coronary Artery Disease on Clopidogrel

Withdrawn before enrolling

Conditions studied: Coronary Artery Disease

In brief

African Americans with coronary artery disease who have been prescribed clopidogrel (also known as Plavix), an antiplatelet drug will be enrolled. The purpose of this study is to help identify why African Americans are at an increased risk of having a major heart attack or stroke after a common procedure to open up blocked arteries with stents. The knowledge to be gained from this study includes: 1. A better understanding of the metabolism of the antiplatelet drug, clopidogrel, and abnormal platelet function in African Americans; this understanding may provide a basis for potential future therapy 2. A better understanding of challenges to taking clopidogrel as prescribed by a doctor and opinions about a genetic test related to this medicine.

Key facts

Study ID

NCT04619381

Run by

Vanderbilt University Medical Center

People needed

0

Starts

2021-03-19

Expected to finish

2021-03-19

Last updated by the study team

2021-04-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older
• Sex: Male and Female
• Race: Self-identified as African American
• History of percutaneous coronary intervention in the past 12 months
• Currently taking aspirin and clopidogrel for at least one month and up to one year
• English speaking

You may not qualify if…

• Use of nonsteroidal anti-inflammatory drugs
• Pregnancy will be excluded in women of child-bearing potential using urine pregnancy test

Where it is running

• Vanderbilt University Medical Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.